Alerts will be sent to your verified email
Verify Email
AUROPHARMA
|
Aurobindo Pharma
|
Mankind Pharma
|
Zydus Lifesciences
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Number of ANDA's Filed in USA
|
879.0 . | 67.0 . | 505.0 . |
|
Number of ANDA's Approved By USFDA
|
750.0 . | 48.0 . | 428.0 . |
|
US DMF Filings
|
315.0 . | n/a | 147.0 . |
|
Europe DMF Filings
|
2127.0 . | n/a | n/a |
|
R&D as a % of Total Sales
|
4.7 % | 2.2 % | 8.8 % |
|
Financials
|
|||
|
5 yr Average ROE
|
12.72 % | 20.33 % | 18.47 % |
|
5yr average Equity Multiplier
|
1.46 | 1.46 | 1.52 |
|
5yr Average Asset Turnover Ratio
|
0.68 | 0.81 | 0.66 |
|
5yr Avg Net Profit Margin
|
12.5 % | 17.68 % | 19.02 % |
|
Price to Book
|
2.22 | 5.4 | 3.43 |
|
P/E
|
22.35 | 46.43 | 17.59 |
|
5yr Avg Cash Conversion Cycle
|
-46.37 Days | -13.08 Days | -84.89 Days |
|
Inventory Days
|
59.62 Days | 59.06 Days | 36.38 Days |
|
Days Receivable
|
30.33 Days | 34.35 Days | 36.93 Days |
|
Days Payable
|
121.28 Days | 121.69 Days | 160.15 Days |
|
5yr Average Interest Coverage Ratio
|
43.54 | 46.07 | 30.19 |
|
5yr Avg ROCE
|
15.27 % | 25.06 % | 19.65 % |
|
5yr Avg Operating Profit Margin
|
19.22 % | 24.62 % | 24.4 % |
|
5 yr average Debt to Equity
|
0.19 | 0.16 | 0.17 |
|
5yr CAGR Net Profit
|
-8.16 % | 9.49 % | 16.23 % |
|
5yr Average Return on Assets
|
8.64 % | 14.46 % | 12.22 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
51.82 % | 72.66 % | 75.0 % |
|
Share Pledged by Promoters
|
17.5 % | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-0.01 % | -3.84 % | 0.02 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
12.02 % | 7.47 % | -0.85 % |
|
Aurobindo Pharma
|
Mankind Pharma
|
Zydus Lifesciences
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Asset Break-Up
|
Asset Break-Up
|
-
|
Asset Break-Up
|